Rafael Holdings Completes Merger with Cyclo Therapeutics

Rafael Holdings ( (RFL) ) has provided an announcement.

On March 25, 2025, Rafael Holdings completed a merger with Cyclo Therapeutics, marking a significant step in its strategy to develop clinical stage assets. The merger, approved by shareholders, resulted in Rafael issuing Class B common stock to Cyclo shareholders, representing approximately 22% of the combined company. This merger strengthens Rafael’s focus on Trappsol® Cyclo™, a lead clinical asset for treating Niemann-Pick Disease Type C1, with expectations for interim analysis results in mid-2025. Additionally, Markus W. Sieger, former Chairman of Cyclo, joined Rafael’s board, enhancing its leadership with his extensive experience in healthcare and other industries.

More about Rafael Holdings

Rafael Holdings, Inc. is a biotechnology company with interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC. The company focuses on developing clinical stage assets, particularly in areas of high unmet medical need, such as Niemann-Pick Disease Type C1. Rafael Holdings also holds interests in companies like LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Rafael Medical Devices, LLC, and Day Three Labs, Inc.

YTD Price Performance: 17.05%

Average Trading Volume: 35,464

Technical Sentiment Signal: Sell

Current Market Cap: $51.53M

See more data about RFL stock on TipRanks’ Stock Analysis page.